Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Dunaújváros – page 8

198 clinical trials in Dunaújváros, Hungary across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Dunaújváros at a glance
198
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

198 trials in Dunaújváros

Open in trial search

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Previously Used Biologic Treatments

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen - Cilag International

Obesity

Not recruiting

Study on the Effect of Survodutide on Heart Safety in Patients with Obesity and Cardiovascular or Kidney Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim Espana S.A.

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Not Used Biologic Treatments

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen - Cilag International

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren's Syndrome

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Psoriatic arthropathy

Not recruiting

Study of sonelokimab and risankizumab in adults with psoriatic arthritis who did not respond well to previous TNF inhibitor treatment

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:MoonLake Immunotherapeutics AG

Skin ulcer

Not recruiting

Study on the Effectiveness of Allo-APZ2-CVU for Patients with Long-Term, Non-Healing Venous Leg Ulcers

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:ALLO-APZ2-EB
  • Sponsor:Rheacell GmbH & Co. KG

Psoriatic arthropathy

Not recruiting

Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Arteriosclerosis

Not recruiting

Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Study of Durvalumab and Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Astrazeneca AB

Study Comparing AVT16 and Vedolizumab for Adults with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Alvotech Swiss AG

Study on the Effectiveness and Safety of Tanimilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tanimilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Asthma

Not recruiting

Study of rocatinlimab compared to placebo to help adults with Moderate to Severe Asthma

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Dunaújváros

What the registry says about research in the country

01 Cardiovascular and Stroke Research

Innovative trials focusing on atherosclerotic cardiovascular disease prevention and stroke treatment, evaluating new therapeutic approaches for reducing major cardiovascular events.

  • Primary ASCVD Prevention
  • Acute Ischemic Stroke
  • High-Risk TIA Management

Studies aim to demonstrate the effectiveness of novel compounds in preventing cardiovascular complications and improving stroke outcomes.

02 Renal and Metabolic Disorders

Research examining combination therapies for chronic kidney disease with concurrent hypertension, exploring innovative treatment approaches for better patient outcomes.

  • CKD Management
  • Hypertension Control
  • Primary Biliary Cholangitis

Trials focus on evaluating new medications to slow disease progression and improve quality of life.

03 Neurological and Pain Management

Studies investigating novel treatments for episodic migraine, focusing on preventive therapies to reduce headache frequency and severity.

  • Migraine Prevention
  • Headache Management

Research aims to develop effective preventive treatments for patients suffering from recurring migraines.

04 Gastrointestinal and Inflammatory Conditions

Clinical investigations of new therapies for ulcerative colitis, examining both short-term improvement and long-term maintenance treatments.

  • Inflammatory Bowel Disease
  • UC Management
  • Long-term Disease Control

Studies evaluate novel compounds for achieving endoscopic improvement and symptomatic remission.

05 Wound Healing and Regenerative Medicine

Innovative research utilizing stem cell therapy for treating chronic venous ulcers, focusing on wound healing in difficult-to-treat cases.

  • Chronic Wound Management
  • Regenerative Medicine
  • Venous Ulcer Treatment

Trials explore advanced therapeutic approaches for non-healing wounds using cellular treatments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.